NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

XWELL, Inc. (XWEL) Stock Analysis

XWELL, Inc. (XWEL) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

XWEL

$0.98

+$0.01 (+1.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XWEL with… →

XWEL Key Statistics

As of Sep 4, 2026
Trading
Open
$0.96
Previous Close
$0.97
Day's Range
0.96–0.98
52-Week Range
0.26–2.20
Volume
16.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.00
Valuation
Market Cap
$8.38M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.30
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.21
Financials (FY)
Revenue (FY)
$29.21M−13.83%
Net Income (FY)
−$16.99M
Profit marginThe share of revenue left as profit after all costs and taxes.
−82.90%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.59M
1-Year Return
−11.71%
Dividend and dates
Avg Volume
105.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XWEL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+113.04%
2025−69.54%
2024−13.22%
2023−75.83%
2022−82.18%
2021+69.75%
2020−40.80%
2019−79.06%
2018−88.32%
2017−35.68%
2016 (partial year)+1.43%

As of September 4, 2026.

XWEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$29.21M−$16.99M−58.2%
2024$33.90M−$16.85M−49.7%
2023$30.11M−$27.74M−92.1%
2022$55.94M−$32.84M−58.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$29.21M$7.51M−$9.36M−$16.99M−58.2%
2024$33.90M$8.92M−$12.10M−$16.85M−49.7%
2023$30.11M$3.68M−$19.30M−$27.74M−92.1%
2022$55.94M$12.05M−$24.55M−$32.84M−58.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XWEL Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricXWELDiagnostics & Research medianvs median
P/S ratio0.304.990.1x the median
Profit margin−82.90%0.00%82.9 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values XWELL, Inc. (XWEL) at $8.38M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 175.

The most recent close on file for XWEL is $0.98, dated September 4, 2026. That is +$0.01 (+1.03%) against the previous close. Over the past 52 weeks the price has ranged from $0.26 to $2.20. The latest close sits 276.92% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $29.21M. Against the prior fiscal year total of $33.90M, that is a change of −13.83%. The same year closed with a net loss of $16.99M. Profit margin runs at −82.9%. That is 82.9 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −5.21.

Across the 4 fiscal years on file, revenue moves from $55.94M in 2022 to $29.21M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.3 times revenue. On price-to-sales that is 0.1 times the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

The trailing one-year price return is −11.71%. Across 10 years the annualized return works out at −54.20%. Beta against the wider market is reported at 1. Daily returns over the trailing 10 years annualize to a volatility of 140.69%.

Growth & Income

No dividend is on file for XWEL.

Across the complete calendar years on file, 2021 returned +69.75% and 2018 returned −88.32%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is +113.04%.

Peer Comparison

XWELL, Inc. (XWEL) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
XWELL, Inc. XWEL $8.38M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. XWELL, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About XWELL, Inc.

XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers COVID-19 and other medical testing to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. customs and border protection agents; aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program; and various services and support, including technical support services and advanced services. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. It offers its services through stores and kiosks, as well as online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.

Visit website →